Isotechnika Pharma Inc. (TSX: ISA) is proud to announce the publication of the PROMISE study in the American Journal of Transplantation (AJT), one of the most respected journals in transplant medicine. The PROMISE study was a Phase 2b, 6-month, randomized, open-label study of three concentration-controlled groups of voclosporin (VCS), low, medium, and high, compared to tacrolimus (TAC) in 334 low-risk kidney transplantation recipients at 36 sites in the United States and 4 sites in Canada. The primary endpoint of the study was to demonstrate noninferiority of at least one of the three VCS groups in preventing acute rejection compared to TAC after kidney transplantation.